Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $80.46 -0.81%
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 GAAP EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $23.8 million versus the consensus estimate of $23.46 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $115-125 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- TETRA Technologies (TTI) Tops Q3 EPS by 1c, Beats on Revenue
- Greenlight Captial Re (GLRE) Misses Q2 EPS by 40c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
